Screening method and therapeutic agent for mental disorder
AssigneeFujita Health University
InventorsKazuo KUNISAWA, Akihiro MOURI, Toshitaka NABESHIMA
Life of this patent
Estimating the term…
Abstract
Provided are a novel therapeutic agent for a mental disorder and a screening method for a therapeutic agent for a mental disorder. The therapeutic agent for a mental disorder includes clemastine or a pharmacologically acceptable salt thereof as an active ingredient. According to the therapeutic agent of the present invention, myelin sheath abnormality and brain dysfunction due to a mental disorder can be mitigated. Further, through use of the screening method of the present invention, a therapeutic agent for a mental disorder can be screened for.
Claims20
A therapeutic agent for a mental disorder in a subject, comprising clemastine or a pharmacologically acceptable salt thereof as an active ingredient.
A screening method for a therapeutic agent for a mental disorder in a subject, comprising screening for an oligodendrocyte differentiation enhancing substance.
A method of examining prognosis of a mental disorder in a subject, comprising measuring, in a test sample collected from a human subject, one or a plurality of kinds of molecules selected from oligodendrocyte markers, oligodendrocyte differentiation modulators, oligodendrocyte differentiation regulators, and oligodendrocyte-derived products.
A method of treating a mental disorder in a subject, comprising administering an effective amount of clemastine or a pharmacologically acceptable salt thereof to a person in need thereof.
Dependencies are inferred from the claim text.